Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients

Johnson & Johnson says new patient-experience findings from its Phase 2 DAHLIAS study of nipocalimab in Sjögren’s disease show mouth dryness as the top symptom improvement patients prioritize. In interviews after the treatment period, 96% of surveyed participants cited mouth dryness as the most important change, followed by eye dryness, fatigue and joint pain, with vaginal dryness reported by 49% of women. The company links those insights to earlier Phase 2 results showing a 50% increase in saliva production in more than twice as many patients on nipocalimab 15 mg/kg compared with placebo. J&J will present 23 nipocalimab abstracts at ACR Convergence 2026, while two Phase 3 studies are ongoing.